Who makes Lidocaine aerosol 2.4% topical?

Lidocaine aerosol 2.4% topical is developed by Jiangang Song.

What development phase is Lidocaine aerosol 2.4% topical in?

Lidocaine aerosol 2.4% topical is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Lidocaine aerosol 2.4% topical

Jiangang Song · FDA-approved active Small molecule Quality 13/100

At a glance

Generic name	Lidocaine aerosol 2.4% topical
Sponsor	Jiangang Song
Drug class	Local anesthetic
Target	Voltage-gated sodium channels
Modality	Small molecule
Therapeutic area	Pain
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of Lidocaine Aerosol Plus Low-dose Cisatracurium vs Conventional-dose Cisatracurium on Intubation Conditions in ERCP - A Randomized Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lidocaine aerosol 2.4% topical CI brief — competitive landscape report
Lidocaine aerosol 2.4% topical updates RSS · CI watch RSS
Jiangang Song portfolio CI